Pramipexole-contained pharmaceutical composition capable of being dispersed in mouth

Abstract

The invention relates to a pramipexole-contained pharmaceutical composition capable of being dispersed in a mouth, which is characterized by containing pramipexole or medicinal salt thereof or pharmaceutically acceptable auxiliary materials. The invention is used for the technical field of medicines.

Description

technical field [0001] The present invention relates to an orally dispersible solid pharmaceutical form for oral administration of pramipexole or a pharmaceutically acceptable salt thereof without the need for drinking water and without swallowing problems. Background technique [0002] Pramipexole is a known dopamine D2 receptor agonist. It is structurally distinct from ergot-derived drugs such as bromocriptine or pergolide. It is also pharmacologically unique in that it is a full agonist and has receptor selectivity for the dopamine D2 family of dopamine receptors. [0003] The dose of pramipexole to achieve the desired therapeutic effect is 0.125 mg to 1.5 mg, usually given as an immediate release tablet. Many people have trouble swallowing regular tablets, and the size of the tablets is often not to be ignored. Problems with swallowing the drug (choking; choking due to throat obstruction) are often the cause of poor compliance with the dosing regimen or even discontin...

AI Technical Summary

Problems solved by technology

[0007] The pharmaceutical composition provided by the present invention not only solves the known problems of the tablet form which needs to be swallowed, but also provides an excellent medical service which can improve the quality of life of the patient especially

Images